CAS 123441-03-2|Rivastigmine

Introduction：Basic information about CAS 123441-03-2|Rivastigmine, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. Rivastigmine BiologicalActivity
3. Chemical & Physical Properties
4. Safety Information
5. Synonyms

Common Name	Rivastigmine
CAS Number	123441-03-2	Molecular Weight	250.34
Density	1.0±0.1 g/cm3	Boiling Point	316.2±34.0 °C at 760 mmHg
Molecular Formula	C₁₄H₂₂N₂O₂	Melting Point	/
MSDS	/	Flash Point	145.0±25.7 °C

Names

Name	rivastigmine
Synonym	More Synonyms

Rivastigmine BiologicalActivity

Description	Rivastigmine, an cholinesterase inhibitor(IC50= 5.5 uM), inhibits both butyrylcholinesterase and acetylcholinesteraseIC50 value: 5.5 uMTarget: AChERivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease. The drug can be administered orally or via a transdermal patch; the latter form reduces the prevalence of side effects, which typically include nausea and vomiting. The drug is eliminated through the urine, and appears to have relatively few drug-drug interactions. Rivastigmine, a cholinesterase inhibitor, inhibits both butyrylcholinesterase and acetylcholinesterase. It is thought to work by inhibiting these cholinesterase enzymes, which would otherwise break down the brain chemical acetylcholine.
Related Catalog	Signaling Pathways >>Neuronal Signaling >>AChEResearch Areas >>Neurological Disease
References	[1]. Kurz A, Farlow M, Lefèvre G. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review. Int J Clin Pract. 2009 May;63(5):799-805. [2]. Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther. 1998 Jul-Aug;20(4):634-47. [3]. Stryjer R, Ophir D, Bar F et al. Rivastigmine treatment for the prevention of electroconvulsive therapy-induced memory deficits in patients with schizophrenia. Clin Neuropharmacol. 2012 Jul-Aug;35(4):161-4. [4]. Han HJ, Lee JJ, Park SA et al. Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer's disease. J Clin Neurol. 2011 Sep;7(3):137-42.

Description

Rivastigmine, an cholinesterase inhibitor(IC50= 5.5 uM), inhibits both butyrylcholinesterase and acetylcholinesteraseIC50 value: 5.5 uMTarget: AChERivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease. The drug can be administered orally or via a transdermal patch; the latter form reduces the prevalence of side effects, which typically include nausea and vomiting. The drug is eliminated through the urine, and appears to have relatively few drug-drug interactions. Rivastigmine, a cholinesterase inhibitor, inhibits both butyrylcholinesterase and acetylcholinesterase. It is thought to work by inhibiting these cholinesterase enzymes, which would otherwise break down the brain chemical acetylcholine.

Related Catalog

Signaling Pathways >>Neuronal Signaling >>AChEResearch Areas >>Neurological Disease

References

[1]. Kurz A, Farlow M, Lefèvre G. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review. Int J Clin Pract. 2009 May;63(5):799-805.

[2]. Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther. 1998 Jul-Aug;20(4):634-47.

[3]. Stryjer R, Ophir D, Bar F et al. Rivastigmine treatment for the prevention of electroconvulsive therapy-induced memory deficits in patients with schizophrenia. Clin Neuropharmacol. 2012 Jul-Aug;35(4):161-4.

[4]. Han HJ, Lee JJ, Park SA et al. Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer's disease. J Clin Neurol. 2011 Sep;7(3):137-42.

Chemical & Physical Properties

Density	1.0±0.1 g/cm3
Boiling Point	316.2±34.0 °C at 760 mmHg
Molecular Formula	C₁₄H₂₂N₂O₂
Molecular Weight	250.34
Flash Point	145.0±25.7 °C
PSA	147.84000
LogP	2.14
Vapour Pressure	0.0±0.7 mmHg at 25°C
Index of Refraction	1.518
InChIKey	XSVMFMHYUFZWBK-NSHDSACASA-N
SMILES	CCN(C)C(=O)Oc1cccc(C(C)N(C)C)c1

Safety Information

Hazard Codes	Xi

Synonyms

Carbamic acid, N-ethyl-N-methyl-, 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester

[3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-ethyl-N-methylcarbamate

MFCD03700731

(S)-N-ethyl-3-[(1-dimethylamino)ethyl]-N-methylphenylcarbamate

Rivastigmine

N-Ethyl-N-methylcarbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl-ester

(S)-3-(1-(dimethylamino)ethyl)phenyl ethyl(methyl)carbamate

Ethylmethylcarbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester

3-((1S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate

carbamic acid, ethyl(methyl)-, 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester

3-[(1S)-1-(Dimethylamino)ethyl]phenyl ethyl(methyl)carbamate

Recommended......